Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated. Costs were somewhat higher than we had forecast as was the cash burn. A rights issue of SEK200m was announced, which will fund Pepaxti and the preclinical pipeline.
LÄS MER
